User profiles for C. C. Felder
Christian C. FelderSenior Scientific Fellow, Karuna Therapeutics Verified email at karunatx.com Cited by 25817 |
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
…, G Cabral, P Casellas, WA Devane, CC Felder… - Pharmacological …, 2002 - ASPET
Two types of cannabinoid receptor have been discovered so far, CB 1 (2.1: CBD:1:CB1:),
cloned in 1990, and CB 2 (2.1:CBD:2:CB2:), cloned in 1993. Distinction between these …
cloned in 1990, and CB 2 (2.1:CBD:2:CB2:), cloned in 1993. Distinction between these …
Muscarinic acetylcholine receptors: signal transduction through multiple effectors
CC Felder - The FASEB Journal, 1995 - Wiley Online Library
… Felder, CC Muscarinic acetylcholine … FELDER … Gusovsky, F, Leuden, JE, Kohn, EC,
and Felder, CC (1993) Muscarinic receptor-mediated tyrosine …
and Felder, CC (1993) Muscarinic receptor-mediated tyrosine …
Cannabinoid receptors and their endogenous agonists
▪ Abstract Marijuana has been in use for over 4000 years as a therapeutic and as a recreational
drug. Within the past decade, two cannabinoid receptor types have been identified, their …
drug. Within the past decade, two cannabinoid receptor types have been identified, their …
[PDF][PDF] Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
CC Felder, KE Joyce, EM Briley, J Mansouri… - Molecular …, 1995 - academia.edu
The recently cloned GB2 cannabinoid receptor subtype was stably transfected into AtT-20
and Chinese hamster ovary cells to compare the binding and signal transduction properties of …
and Chinese hamster ovary cells to compare the binding and signal transduction properties of …
Activation and allosteric modulation of a muscarinic acetylcholine receptor
Despite recent advances in crystallography and the availability of G-protein-coupled receptor
(GPCR) structures, little is known about the mechanism of their activation process, as only …
(GPCR) structures, little is known about the mechanism of their activation process, as only …
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 …
Cannabinoids act at the CB1 receptor to inhibit adenylate cyclase activity via a pertussis
toxin-sensitive G-protein. Within the striatum, CB1 receptors have been shown to be localized …
toxin-sensitive G-protein. Within the striatum, CB1 receptors have been shown to be localized …
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor
…, P Carter, FP Bymaster, AB Leese, CC Felder - … of Pharmacology and …, 2002 - ASPET
The first endocannabinoid, anandamide, was discovered in 1992. Since then, two other
endocannabinoid agonists have been identified, 2-arachidonyl glycerol and, more recently, …
endocannabinoid agonists have been identified, 2-arachidonyl glycerol and, more recently, …
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Cannabinoids have immunomodulatory as well as psychoactive effects. Because the central
cannabinoid receptor (cannabinoid CB 1 receptor) is highly expressed in many neuronal …
cannabinoid receptor (cannabinoid CB 1 receptor) is highly expressed in many neuronal …
Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
CC Felder, EM Briley, J Axelrod… - Proceedings of the …, 1993 - National Acad Sciences
Arachidonylethanolamide (anandamide), a candidate endogenous cannabinoid ligand, has
recently been isolated from porcine brain and displayed cannabinoid-like binding activity to …
recently been isolated from porcine brain and displayed cannabinoid-like binding activity to …
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
…, FP Bymaster, DL McKinzie, CC Felder - American Journal of …, 2008 - Am Psychiatric Assoc
Objective: There are significant unmet needs in the treatment of schizophrenia, especially
for the treatment of cognitive impairment, negative syndrome, and cognitive function. …
for the treatment of cognitive impairment, negative syndrome, and cognitive function. …